Form 4: VivoSim Labs Director Awarded 15,000 RSUs
Insider Transaction Report
VivoSim Labs Director David Gobel received a grant of 15,000 restricted stock units, vesting in early 2027 or upon the next annual meeting.
Summary
- David Gobel, a Director of VivoSim Labs, Inc. (VIVS), was granted 15,000 shares of common stock in the form of restricted stock units (RSUs).
- The transaction occurred on January 27, 2026, with an acquisition price of $0.00 per share.
- Following this transaction, David Gobel directly beneficially owns 15,000 shares of common stock.
- The restricted stock units are scheduled to vest on the earlier of January 27, 2027, or the date of the next annual meeting of stockholders held by VivoSim Labs, Inc.
- Vesting of the RSUs is subject to acceleration in the event of a change of control of the company.
- A Power of Attorney was executed on January 28, 2026, appointing Keith Murphy and Norman Staskey as attorneys-in-fact to file Section 16 reports and Rule 144 forms on behalf of David Gobel.
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a moderately positive event, as it represents a standard practice for aligning director incentives with shareholder interests, without indicating any immediate operational or financial changes.
Positives
- The grant of restricted stock units to a director aligns management's interests with those of shareholders, as the value of the compensation is tied to the company's stock performance.
- Equity-based compensation is a common practice to attract and retain qualified directors and executives.
Negatives
- The transaction involves a grant of shares at a $0.00 price, meaning no direct cash proceeds for the company from this specific issuance.
Industry Context
StockSavvy.ai notes that the grant of restricted stock units to directors is a standard practice across various industries, particularly in technology and biotech sectors, to incentivize long-term performance and align leadership interests with shareholder value creation. This type of compensation is a common component of executive and director remuneration packages.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Authorization of Attorney-in-Fact | David Gobel executed a Power of Attorney, authorizing Keith Murphy and Norman Staskey to act as his attorneys-in-fact for filing SEC Forms 3, 4, 5, and 144 related to his holdings and transactions in VivoSim Labs, Inc. securities. | 01/28/2026 | This streamlines the process for insider trading compliance filings, ensuring timely and accurate reporting on behalf of the director. |
Stakeholder Impact
- Shareholders: The equity grant aligns the director's financial interests with the long-term performance of the company, potentially benefiting shareholders through improved governance and strategic decisions.
Next Steps
- Vesting of the 15,000 restricted stock units on the earlier of January 27, 2027, or the date of the next annual meeting of stockholders.
- Potential acceleration of vesting in the event of a change of control.
Key Dates
| Date | Description |
|---|---|
| 01/27/2026 | Grant of 15,000 restricted stock units to Director David Gobel. |
| 01/28/2026 | Execution date of the Power of Attorney by David Gobel. |
| 01/29/2026 | Signature date of the Form 4 filing by attorney-in-fact. |
| 01/27/2027 | Earliest vesting date for the restricted stock units. |
Keywords
VivoSim Labs, VIVS, Restricted Stock Units, RSU, Insider Transaction, Form 4, Director Compensation, Equity Grant, Corporate Governance
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.